Journal
CELL REPORTS
Volume 25, Issue 8, Pages 2083-+Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2018.10.084
Keywords
-
Categories
Funding
- NIH [DK094934, DK114031, DK086267]
- CT Stem Cell Fund
- Yale Cooperative Center of Excellence in Hematology [U54DK106857]
- Yale-Fluidigm Single Cell Grant Program
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007974] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK094934, U54DK106857, R01DK114031] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Megakaryocytic- erythroid progenitors (MEPs) give rise to the cells that produce red blood cells and platelets. Although the mechanisms underlying megakaryocytic (MK) and erythroid (E) maturation have been described, those controlling their specification from MEPs are unknown. Single-cell RNA sequencing of primary human MEPs, common myeloid progenitors (CMPs), megakaryocyte progenitors, and E progenitors revealed a distinct transitional MEP signature. Inferred regulatory transcription factors (TFs) were associated with differential expression of cell cycle regulators. Genetic manipulation of selected TFs validated their role in lineage specification and demonstrated coincident modulation of the cell cycle. Genetic and pharmacologic modulation demonstrated that cell cycle activation is sufficient to promote E versus MK specification. These findings, obtained from healthy human cells, lay a foundation to study the mechanisms underlying benign and malignant disease states of the megakaryocytic and E lineages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available